FOLH1 and neoplasm: We conducted several preclinical evaluations of 177Lu-PSMA-617 in tumor-bearing mice, including the development of 177Lu radiolabeling and quality control techniques, assessments of radiopharmaceutical stability, cell binding affinity, nuclear imaging, in vivo biodistribution, pharmacokinetics, radiation dosimetry, and antitumor efficacy.